Cargando…

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?

Drug resistance (DR) of cancer cells leading to relapse is a huge problem nowadays to achieve long-lasting cures for cancer patients. This also holds true for the incurable hematological malignancy multiple myeloma (MM), which is characterized by the accumulation of malignant plasma cells in the bon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muylaert, Catharina, Van Hemelrijck, Lien Ann, Maes, Anke, De Veirman, Kim, Menu, Eline, Vanderkerken, Karin, De Bruyne, Elke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434119/ https://www.ncbi.nlm.nih.gov/pubmed/36059621 http://dx.doi.org/10.3389/fonc.2022.979569

Ejemplares similares

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
por: Verheye, Emma, et al.
Publicado: (2022)

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
por: Oudaert, Inge, et al.
Publicado: (2022)

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
por: De Beck, Lien, et al.
Publicado: (2018)

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma
por: Vlummens, Philip, et al.
Publicado: (2019)

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
por: De Smedt, Eva, et al.
Publicado: (2018)

The genetic landscape of 5T models for multiple myeloma
por: Maes, Ken, et al.
Publicado: (2018)

The therapeutic potential of cell cycle targeting in multiple myeloma
por: Maes, Anke, et al.
Publicado: (2017)

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells
por: Wang, Jinheng, et al.
Publicado: (2015)

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
por: Yan, Siyang, et al.
Publicado: (2019)

P860: THE DE NOVO DNA METHYLTRANSFERASE DNMT3B PLAYS AN IMPORTANT ROLE IN MM CELL GROWTH, CLONOGENICITY AND DRUG RESPONSE
por: Muylaert, C., et al.
Publicado: (2022)

Metabolic Features of Multiple Myeloma
por: El Arfani, Chaima, et al.
Publicado: (2018)

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
por: Fan, Rong, et al.
Publicado: (2023)

Novel strategies to target the ubiquitin proteasome system in multiple myeloma
por: Lub, Susanne, et al.
Publicado: (2015)

Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis
por: Oudaert, Inge, et al.
Publicado: (2022)

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers
por: Fan, Rong, et al.
Publicado: (2022)

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
por: Vlummens, Philip, et al.
Publicado: (2022)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells
por: Lub, Susanne, et al.
Publicado: (2015)

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
por: Hu, Jinsong, et al.
Publicado: (2012)

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
por: Faict, Sylvia, et al.
Publicado: (2018)

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma
por: Maes, Anke, et al.
Publicado: (2019)

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma
por: Wang, Jinheng, et al.
Publicado: (2016)

Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2014)

Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells
por: De Beule, Nathan, et al.
Publicado: (2017)

Correction: Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells
por: De Beule, Nathan, et al.
Publicado: (2018)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
por: Bieghs, Liesbeth, et al.
Publicado: (2010)

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
por: Faict, Sylvia, et al.
Publicado: (2019)

PB1973: INHIBITION OF LACTATE EXPORTERS INDUCES DIRECT ANTI-TUMOR EFFECTS AND COUNTERS IMMUNE SUPPRESSION IN MULTIPLE MYELOMA
por: Van der Vreken, A., et al.
Publicado: (2022)

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Exosomes in multiple myeloma: from bench to bedside
por: Menu, Eline, et al.
Publicado: (2022)

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
por: Bieghs, Liesbeth, et al.
Publicado: (2016)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
por: De Veirman, Kim, et al.
Publicado: (2015)

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
por: Emde-Rajaratnam, Martina, et al.
Publicado: (2023)

Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
por: De Veirman, Kim, et al.
Publicado: (2014)

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma
por: Maes, Anke, et al.
Publicado: (2019)

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
por: Nylund, Patrick, et al.
Publicado: (2021)

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
por: Bieghs, Liesbeth, et al.
Publicado: (2014)

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
por: Favreau, Mérédis, et al.
Publicado: (2016)

Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
por: Xu, Song, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n5durfqgg0q3dv4oda06jvlolb